Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Free Cash Flow (2016 - 2025)

Voyager Therapeutics' Free Cash Flow history spans 11 years, with the latest figure at -$28.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 95.59% year-over-year to -$28.7 million; the TTM value through Dec 2025 reached -$132.9 million, down 605.72%, while the annual FY2025 figure was -$132.9 million, 605.72% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$28.7 million at Voyager Therapeutics, up from -$31.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $123.1 million in Q1 2023 and bottomed at -$38.6 million in Q1 2025.
  • The 5-year median for Free Cash Flow is -$20.9 million (2021), against an average of -$7.2 million.
  • The largest annual shift saw Free Cash Flow soared 259.83% in 2023 before it plummeted 8510.32% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $9.6 million in 2021, then plummeted by 211.37% to -$10.7 million in 2022, then tumbled by 129.11% to -$24.5 million in 2023, then surged by 40.1% to -$14.7 million in 2024, then crashed by 95.59% to -$28.7 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Free Cash Flow are -$28.7 million (Q4 2025), -$31.3 million (Q3 2025), and -$34.4 million (Q2 2025).